BuzzSparks.org

Concert Pharmaceuticals


Biotechnology company

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative...

Founded in 2006
Homepage:
Total money raised: $99.5M

Corporate Headquarters

02421 99 Hayden Avenue
Suite 500

Lexington
Lexington
USA MA

Phone: 781.860.0045

Updated on Feb 13, 2014
Concert Pharmaceuticals at CrunchBase
Richard Aldrich Chairman of the Board
Roger Tung Founder, President, CEO & Board of Directors
Nancy Stuart COO
Robert Silverman SVP & General Counsel
Robert Zelle VP & Senior Fellow, Drug Development
Ronald W. Barrett Board of Directors
Stephen J. Hoffman Board of Directors
Wilfred Jaeger Board of Directors
Doug Cole Board of Directors
Richard Aldrich Co - Founder
Douglas G. Cole Board of Directors
Peter Barton Hutt Board of Directors
Helmut M. Schühsler Board of Directors
Past
Steve Bernitz Chief Business Officer
Jonathan Montagu Business Development
Craig Masse Group Leader of Medicinal Chemistry
Jonathan Montagu

February, 2014

Concert Pharmaceuticals IPO
Stock symbol: NASDAQ:CNCE

February, 2012

Concert Pharma snags $200M licensing pact with Avanir    fiercebiotech.com

June, 2011

Concert Pharmaceuticals raised $4M in unattributed round from GlaxoSmithKline

Concert Pharmaceuticals lands $4M milestone pay    masshightech.com

April, 2011

has made two new executive appointments

Concert Pharmaceuticals names Roessel, Sabounjian to exec roles    masshightech.com

February, 2011

Concert Pharmaceuticals, Walter Reed partner on seizure teatment    masshightech.com

November, 2009

Concert Pharmaceuticals to land $12M from HIV drug's clinical study

Mass High Tech    masshightech.com

April, 2008

Concert Pharmaceuticals raised $37M in a Series C round from QVT Financial, GSK Venture Fund, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, Skyline Ventures, TVM Capital, Brookside Capital, New Leaf Venture Partners, Flagship Ventures, Adage Capital Management, and Greylock Partners

November, 2006

Concert Pharmaceuticals raised $48.5M in a Series B round from Flagship Ventures, Brookside Capital, New Leaf Venture Partners, Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial

Concert Pharmaceuticals Raises $48.5 Million in Series B Financing    concertpharma.com

July, 2006

Concert Pharmaceuticals raised $10M in a Series A round from Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners, and QVT Financial

Concert Pharmaceuticals, Inc.,â„¢ Announces Financing of its Series A Round    concertpharma.com

2006

Concert Pharmaceuticals was founded in 2006